At Krka, we understand that settling for second best is not an option when it comes to people’s health. That is why we meticulously plan our drug development process, giving utmost consideration to the needs of patients and the latest scientific insights. During the recent Innovation Day hosted by the Slovenian Chamber of Commerce and Industry, Krka was honoured with both gold and silver awards for our exceptional innovations. The gold award was received for a range of medications designed to manage type 2 diabetes, while the silver award recognised our integrated reference substance management system.
In our unwavering commitment to cater to the needs of patients by providing them with top-quality, secure, and effective treatments, we allocate approximately 10% of our annual sales towards research and development. Given the rapid advancements in science and technology, as well as the growing complexity of the market, ongoing investments in knowledge and cutting-edge equipment are imperative. These investments enable us to pioneer innovative approaches and introduce new products promptly while upholding the high quality and competitiveness of our products.
Dr. Aleš Rotar, Management Board member and Director of Pharmaceutical R&D and Production, expressed our perspective: “The added value of our innovative generics is twofold. Firstly, it lies in advanced formulations developed, manufactured, and evaluated using state-of-the-art technology and equipment. Secondly, it manifests as a significant enhancement in the quality of life for patients. This is exemplified by our new, modern, safe, and effective medicines containing the active ingredient sitagliptin, which is used in managing type 2 diabetes.”